**Anticancer Metallo-drug Development: Transition from Traditional to Unconventional**

Subhendu Karmakar, Marie Curie Fellow

 School of Chemistry, University of Birmingham, Birmingham-B15 2TT, United Kingdom

Chemotherapy is a major component of cancer treatment and platinum drugs are an indispensable part of the treatment regime. But their use has been limited by serious side effects and various types of resistances. We cannot eliminate the use of platinum drugs in clinics, better we can modify their activity by derivatization or developing novel platinum drugs so that we can offer better and improved alternatives of platinum drugs to the oncologists. This approach has been adapted by most of the medicinal chemists across the globe as it saves both the time and cost involved to develop a new chemotherapeutic drug. However, the severity of the disease always demands novel therapeutics with novel mechanisms of action and with improved ability to tackle the complexity of the disease in a target specific manner. The current state of the art approaches of drug design fail to execute the ultimate goal of targeted therapy, nonetheless, following a supramolecular chemistry approach, the same would be achievable.